The Alascca study uses a large dose of aspirin in the treatment of colon cancer

In this video, Michael Cecchini, Md, Data discussed from the Alasca study, which followed patients with colon cancer, which were treated with a large dose of aspirin.

The large randomized clinical study examined a 160 mg dose of aspirin and showed a reduced recurrence of 50% in colorectal patients in stage II and III.

“The challenge here is actually not a tumor sequence in these patients. So we don't know who that has Pik3ca Mutation in the adjuvant environment, ”said Cecchini, extraordinary professor of medical oncology at the Yale School of Medicine,. “I think there have to be some changes in the way we can actually choose the patients in the United States and how the reimbursement would work for us to use something like this in practice.”

Published by:

Sources/disclosures

collapse

Source: Healio interviews

Declarations: Cecchini reports that he received fees for advisory committees from Agenus, Arcus Biosciences, Astrazeneca, Daiichi Sankyo, Incendia Therapeutics, Loxolilly, Regeneron, Sake and Taiho.

Add a topic on E -Mail warnings

Receive an e -mail if new items are published

Please indicate your e -mail address to get an e -mail when new items are published .

“Subscribe to the data action =” Subscribe “>

We could not edit your request. Please try again later. If you continue to have this problem, please contact customerservice@lackinc.com.

Back to Healio